PMV Pharmaceuticals, Inc.
PMVPNasdaq
$1.34
↑ +3.1%Jul 17 close · end-of-day
Price
1Y0.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$71.5M
Enterprise Value
-$22.1M
P/E
—
P/S
—
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
-105.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$78.3M
Free Cash Flow (TTM)
-$75.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-89.1%
ROIC
—
Debt / Equity
—
Net Cash
$93.5M
Return 1Y
+0.8%
Company profile
PMV Pharmaceuticals, Inc. engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
- CEO
- David H. Mack
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- New Jersey
- Website
- pmvpharma.com
Management & directors
- Mack David HenryPresident and CEO
- Carulli MichaelChief Financial Officer
- Jalota DeepikaChief Development Officer
- Ticktin RobertGeneral Counsel & COO
Roles derived from SEC Form 4 filings.
Earnings
PMVP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.340.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$34.9M | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M |
| Net income | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.9M | -$77.7M |
| Diluted EPS | -$2.40 | -$1.28 | -$1.61 | -$1.44 | -$1.14 | -$1.48 |
| Operating cash flow | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M |
| Free cash flow | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$20.2M | -$21.9M | -$25.2M | -$21.6M | -$22.9M | -$22.5M | -$19.2M | -$19.0M |
| Net income | -$1.2M | -$19.2M | -$23.2M | -$17.4M | -$21.2M | -$21.1M | -$18.0M | -$18.0M |
| Diluted EPS | -$0.02 | -$0.37 | -$0.45 | -$0.34 | -$0.41 | -$0.40 | -$0.33 | -$0.34 |
| Operating cash flow | -$1.6M | -$16.8M | -$16.7M | -$18.3M | -$18.3M | -$19.8M | -$17.2M | -$19.7M |
| Free cash flow | -$1.6M | -$16.8M | -$16.7M | -$18.3M | -$18.3M | -$19.8M | -$17.2M | -$19.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-27 | Mack David Henry· President and CEO | Option exercise | 220,643 | $1.37 | $302,280.91 | filing |
| 2025-10-23 | ORBIMED ADVISORS LLC | Sale | 1,000,000 | $1.52 | $1.5M | filing |
| 2025-09-10 | ORBIMED ADVISORS LLC | Sale | 500,000 | $1.80 | $900,000.00 | filing |
| 2025-07-01 | Mack David Henry· President and CEO | Sale | 58,411 | $1.06 | $62,178.51 | filing |
| 2025-07-01 | Jalota Deepika· Chief Development Officer | Sale | 33,065 | $1.06 | $35,197.69 | filing |
| 2025-07-01 | Carulli Michael· Chief Financial Officer | Sale | 28,249 | $1.06 | $30,076.71 | filing |
| 2025-07-01 | Ticktin Robert· General Counsel & COO | Sale | 23,151 | $1.06 | $24,651.18 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.